Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

AstraZeneca shares fall on "hefty" $39-billion Alexion deal

Stock MarketsDec 14, 2020 07:00AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London

By Pushkala Aripaka

(Reuters) -AstraZeneca shares fell as much as 9% on Monday, as investors moved to price in the costs of a $39 billion deal for U.S. biotech company Alexion Pharmaceuticals (NASDAQ:ALXN) that would be the British drugmaker's biggest ever corporate acquisition.

The deal, announced over the weekend, is also one of the biggest in an already bumper year for mergers and acquisitions and at current market prices will be almost two-thirds funded with AstraZeneca (NASDAQ:AZN) shares.

The terms of the deal give Alexion shareholders $60 in cash and about $115 worth of equity per share, working out at a premium of more than $50 per share according to Reuters calculations.

Analysts from two brokerages, Cowen and Liberum, called the price respectively "considerable" and "hefty", while praising the quality of the assets AstraZeneca was buying.

AstraZeneca shares were down 5.9% at 7,676 pence by 1048 GMT, wiping roughly 7 billion pounds ($9.4 billion) off its market value of 107.1 billion pounds, as of its last close.

The deal is a bet on rare-disease and immunology drugs that will aid Chief Executive Pascal Soriot in his bid to broaden AstraZeneca's drug portfolio further after a successful push into cancer treatments.

Some analysts wondered if the $175 per share price tag left room for a competing bid but Soriot said on Saturday that the deal was the result of exclusive talks and that no competitive bidder had been involved.

Shares in Alexion surged to more than $163 a share, enough to suggest investors believed the deal would succeed but stopping well short of pricing in a bidding war. The company would also have to pay AstraZeneca up to $1.2 billion to walk away from the deal.

Alexion shares in 2015 traded as high as $200 a share and the deal follows pressure from hedge fund Elliott Management to complete a sale.

In eight years at the helm https://www.astrazeneca.com/our-company/leadership.html#, Soriot has made AstraZeneca one of the pharmaceutical world's success stories, raising profits and broadening its portfolio.

Shares of the company, however, have now lost around 17% since hitting a peak in July, as rivals Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) moved ahead in the race to get their COVID-19 vaccines approved.

($1 = 0.7455 pounds)

AstraZeneca shares fall on "hefty" $39-billion Alexion deal
 

Related Articles

World stocks at 1-month high as bond yields soften
World stocks at 1-month high as bond yields soften By Reuters - Oct 19, 2021 4

By Saikat Chatterjee LONDON (Reuters) - World stocks climbed to a one-month high on Tuesday as a rally in technology shares and prospects of solid corporate earnings helped...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Kemal Oumer
Kemal Oumer Dec 14, 2020 4:23AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
waw he is best
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email